MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.12
+0.19
+3.85%
After Hours: 5.12 0 0.00% 17:27 05/18 EDT
OPEN
5.06
PREV CLOSE
4.930
HIGH
5.27
LOW
4.920
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
3.790
MARKET CAP
795.99M
P/E (TTM)
-5.5232
1D
5D
1M
3M
1Y
5Y
Gene Therapy Market 2020 - 2027 : Growth Recommendations By Experts
May 12, 2021 (Market Insight Reports) -- Genes are genetic materials composed of deoxyribonucleic acid (DNA), responsible for producing proteins that have a...
Market Insight Reports · 6d ago
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Benzinga · 05/11 16:32
Adaptimmune posts pre-clinical data from mesothelin cancer study
Adaptimmune Therapeutics (ADAP) posts preclinical data from the company's mesothelin HiT program demonstrating antigen-specific tumor cell killing in vitro and complete tumor regression in an animal model.The company's HLA-independent TCR
Seekingalpha · 05/11 12:32
Adaptimmune Says Co's Mesothelin HiT Program At ASGCT 'Demonstrate Antigen-specific Tumor Cell Killing In vitro And Complete Tumor Regression In An Animal Model'
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, reported preclinical data from its HiT targeting mesothelin, being co-developed with Astellas, during a poster presentation at the
Benzinga · 05/11 12:17
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies - PHILADELP...
GlobeNewswire · 05/11 12:00
Adaptimmune Therapeutics Q1 EPS $(0.04) Beats $(0.25) Estimate, Sales $434.00K Miss $1.83M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. This is unchanged from the same period last year. The company
Benzinga · 05/06 12:43
Adaptimmune Reports First Quarter Financial Results and Business Update
GlobeNewswire · 05/06 12:30
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 11:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADAP. Analyze the recent business situations of Adaptimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADAP stock price target is 10.60 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 117.64M
% Owned: 75.67%
Shares Outstanding: 155.47M
TypeInstitutionsShares
Increased
27
4.08M
New
14
1.95M
Decreased
19
2.47M
Sold Out
15
4.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
Chief Executive Officer/Director
Adrian Rawcliffe
Chief Financial Officer
Gavin Wood
Chief Operating Officer
William Bertrand
Vice President/Director of Investor Relations
Sebastien Desprez
Vice President
Paul Stead
Senior Vice President
Elliot Norry
Other
John Lunger
Other
Helen Tayton-Martin
Non-Executive Director
James Noble
Non-Executive Independent Director
Lawrence Alleva
Non-Executive Independent Director
Ali Behbahani
Non-Executive Independent Director
Barbara Duncan
Non-Executive Independent Director
John Furey
Non-Executive Independent Director
Elliott Sigal
Non-Executive Independent Director
Elliot Sigal
Non-Executive Independent Director
Charles Sigal
Non-Executive Independent Director
Tal Zvi Zaks
Non-Executive Independent Director
Tal Zaks
No Data
About ADAP
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.